Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 496

Sort by

Sort Order Select

Journal Articles

FGF-23: a novel actor in stem cell mobilization

Laura M. Calvi

Blood (2021) 137 (11): 1434–1436.

https://doi.org/10.1182/blood.2020010538

Published: 2021

Journal Articles

Dual Anticoagulant Facilitied Peripheral Blood Stem Cell Harvest from Childhood Donors with Low Weight and Low MCV

Li Yue, Chaoke Bu, Zhirui Ma, Chunfu Li, MD, Wenjun Wang, Jun Zhou

Blood (2019) 134 (Supplement_1): 5639.

https://doi.org/10.1182/blood-2019-129585

Published: 2019

Journal Articles

The Role of Macrophages in Bone Marrow Injury and Hematopoietic Reconstitution

Wen Ju, Tiantian Sun, Wenyi Lu, Kailin Xu, MD, Jianlin Qiao, PhD, Lingyu Zeng, MD,PhD

Blood (2019) 134 (Supplement_1): 3729.

https://doi.org/10.1182/blood-2019-127802

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Blood (2019) 134 (Supplement_1): 4575.

https://doi.org/10.1182/blood-2019-127166

Published: 2019

Journal Articles

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

J Christine Ye, MDMSc, Philip S Boonstra, PhD, Daniel F. Boyer, MD PhD, Larry D. Anderson, MD PhD, Brea C. Lipe, MD, Andrew Kin, MD, Erica L. Campagnaro, MD, Matthew J. Pianko, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3191.

https://doi.org/10.1182/blood-2019-132204

Published: 2019

Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Blood (2019) 134 (Supplement_1): 691.

https://doi.org/10.1182/blood-2019-123465

Published: 2019

Journal Articles

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Barbara Jeker, Sarah Farag, Urban Novak, Ulrike Bacher, Behrouz Mansouri Taleghani, Qiyu Li, Thomas Pabst, MD

Blood (2019) 134 (Supplement_1): 1963.

https://doi.org/10.1182/blood-2019-127848

Published: 2019

Journal Articles

Moral Distress, Anxiety, and Others Physical Symptoms Related to Hematopoietic Stem Cell Donation

Cesar Homero Gutierrez-Aguirre, PhD, Olga Graciela Cantu Rodriguez, MD, Fernando De la Garza-Salazar, MD, Rosario Salazar Riojas, Chem., Andres Gomez De Leon, MD, Perla R. Colunga Pedraza, MD, Geraldina Guerrero-González, PhD, Jose Carlos Jaime, MD PhD, Guillermo J. Ruiz-Arguelles, FRCP, MACP, David Gomez-Almaguer, MD, Oscar Gonzalez Llano, MD, Consuelo Mancias, MD

Blood (2019) 134 (Supplement_1): 1967.

https://doi.org/10.1182/blood-2019-131791

Published: 2019

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 2027.

https://doi.org/10.1182/blood-2019-131818

Published: 2019

Journal Articles

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

Daniel Cancilla, BS, Haresh Thakellapalli, Marvin J Meyers, PhD, Michael P. Rettig, PhD, Ezhilarasi Chendamarai, PhD, Stephanie Christ, MS, Darja Karpova, PhD, Peter G Ruminski, BS, Julie K. Ritchey, Dwight M. Morrow, PhD, Michael Prinsen, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 1916.

https://doi.org/10.1182/blood-2019-124373

Published: 2019

Journal Articles

Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Either a β0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene

Ashutosh Lal, MD, Franco Locatelli, MD PhD, Janet L. Kwiatkowski, MD MSCE, Andreas E. Kulozik, MD PhD, Evangelia Yannaki, MD, John B. Porter, MA MDFRCP FRCPath, Isabelle Thuret, MD, Martin G. Sauer, MD, Heidi Elliot, Ying Chen, PhD, Richard A. Colvin, MD PhD, Alexis A. Thompson, MD MPH

Blood (2019) 134 (Supplement_1): 815.

https://doi.org/10.1182/blood-2019-128482

Published: 2019

Journal Articles

Oncostatin M Is a Novel Niche Factor That Restrains Hematopoietic Stem Cell Mobilization in Response to G-CSF and CXCR4 Antagonist Plerixafor

Kavita Bisht, PhD, Crystal McGirr, Kylie A Alexander, Whitney Fleming, Natalie Sims, Gerhard Müller- Newen, Ingrid G Winkler, PhD, Jean-Pierre Levesque, PhD

Blood (2019) 134 (Supplement_1): 4469.

https://doi.org/10.1182/blood-2019-127431

Published: 2019

Journal Articles

Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma

Abdullah S. Al Saleh, MBBS, M Hasib Sidiqi, MBBS, Morie A. Gertz, MD, Eli Muchtar, MD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Suzanne R. Hayman, MD, Prashant Kapoor, MD, Francis K. Buadi, MB, CHB, Angela Dispenzieri, MD, David Dingli, MD PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 4505.

https://doi.org/10.1182/blood-2019-131380

Published: 2019

Journal Articles

Are We Choosing Mobilization Regimens for Autologous Stem Cell Transplantation in Multiple Myeloma Wisely?: A Single Centre Comparison of GCSF+/-Plerixafor Vs Cyclophosphamide/GCSF+/- Plerixafor

Chloe Yang, MD, Mina Dehghani, MD, Wilma Hopman, MSc, Sita D. Bhella, MD

Blood (2019) 134 (Supplement_1): 2136.

https://doi.org/10.1182/blood-2019-128819

Published: 2019

Journal Articles

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2018-99-112109

Published: 2018

Journal Articles

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Hatem Alahwal, MPH, MBBS, Parv Chapani, Diego Villa, MD FRCPC, Yasser Abou Mourad, MD, Maryse Power, MD, Stephen H. Nantel, MD, David Sanford, MD, Gayatri Sreenivasan, BSc, MD, Heather J. Sutherland, MD PhD, Laurie H Sehn, MD MPH, Cynthia L. Toze, MD FRCPC, MSc, Raewyn Broady, MBChB, Kevin Song, MD, Paul Yenson, MD BSc, FRCPC, Alina S. Gerrie, MD MPH

Blood (2018) 132 (Supplement 1): 4556.

https://doi.org/10.1182/blood-2018-99-114371

Published: 2018

Journal Articles

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Nadine Abdallah, MD, Seongho Kim, PhD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 4557.

https://doi.org/10.1182/blood-2018-99-118400

Published: 2018

Journal Articles

Novel Evidence That Extracellular Nucleotides and Nucleosides Regulate the Expression of Heme Oxygenase 1 (HO-1) in Opposite Ways in Hematopoietic Stem/Progenitor Cells (HSPCs), Which Explains Why ATP Enhances Mobilization of HSPCs, While Its Metabolite Adenosine Inhibits This Process

Mateusz Adamiak, PhD, Kamila Bujko, MS, Monika Plonka, MD, Magdalena Kucia, PhD DSci, Janina Ratajczak, MD PhD DSci, Mariusz Z Ratajczak, MD PhD DSci

Blood (2018) 132 (Supplement 1): 4528.

https://doi.org/10.1182/blood-2018-99-110634

Published: 2018

Journal Articles

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Anton Hagenbeek, MD PhD, Josée M Zijlstra, MD, Wouter J Plattel, MD, Franck Morschhauser, MD, Petronella J Lugtenburg, MD PhD, Pauline Brice, MD, Martin Hutchings, MD, Thomas Gastinne, MD, Roberto D Liu, Coreline N Burggraaf, MD, Marcel Nijland, MD, Sanne H Tonino, MD PhD, Harm van Tinteren, MSc, Marta I Lopez Yurda, MSc, Marie José Kersten, MD PhD

Blood (2018) 132 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2018-99-112235

Published: 2018

NARROW

FGF-23: a novel actor in stem cell mobilization

Dual Anticoagulant Facilitied Peripheral Blood Stem Cell Harvest from Childhood Donors with Low Weight and Low MCV

The Role of Macrophages in Bone Marrow Injury and Hematopoietic Reconstitution

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Moral Distress, Anxiety, and Others Physical Symptoms Related to Hematopoietic Stem Cell Donation

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Either a β0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene

Oncostatin M Is a Novel Niche Factor That Restrains Hematopoietic Stem Cell Mobilization in Response to G-CSF and CXCR4 Antagonist Plerixafor

Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma

Are We Choosing Mobilization Regimens for Autologous Stem Cell Transplantation in Multiple Myeloma Wisely?: A Single Centre Comparison of GCSF+/-Plerixafor Vs Cyclophosphamide/GCSF+/- Plerixafor

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Novel Evidence That Extracellular Nucleotides and Nucleosides Regulate the Expression of Heme Oxygenase 1 (HO-1) in Opposite Ways in Hematopoietic Stem/Progenitor Cells (HSPCs), Which Explains Why ATP Enhances Mobilization of HSPCs, While Its Metabolite Adenosine Inhibits This Process

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only